In part 2 of our MASLD series, Sven Francque outlines that resmetirom is now approved in F2-F3 fibrosis in parts of Europe, semaglutide has produced positive phase 3 data in MASH, and the guideline is being updated.
Tune in now:
🔗 https://bit.ly/44R97K3
We’ve explored how much of this burden is preventable – from the role of nutrition and ultra-processed foods 🍽️ to the life-saving potential of early detection through screening 🩺